The company plans to launch XEMBIFY®, its 20% subcutaneous immunoglobulin for primary and secondary immunodeficiencies, in France, Spain and the U.K. as soon as the third quarter of 2022 Grifols solidifies its IG leadership and further expands the innovative reach of its plasma-derived medicines to benefit patients Already available in the U.S., XEMBIFY ® has proven to be safe, efficacious and tolerable and is formulated for a broad range of patients with immunodeficiencies.
↧